The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Open accessPublished version of a preprint
Abstract
Ipilimumab improves survival in advanced melanoma and can induce immune-mediated tumor vasculopathy. Besides promoting angiogenesis, vascular endothelial growth factor (VEGF) suppresses dendritic cell maturation and modulates lymphocyte endothelial trafficking. This study investigated the combination of CTLA4 blockade with ipilimumab and VEGF inhibition with bevacizumab. Patients with metastatic melanoma were treated in four dosing cohorts of ipilimumab (3 or 10 mg/kg) with four doses at 3-week intervals and then every 12 weeks, and bevacizumab (7.5 or 15 mg/kg) every 3 weeks. Forty-six patients were treated. Inflammatory events included giant cell arteritis (n = 1), hepatitis (n = 2), and uveitis (n = 2). On-treatment tumor biopsies revealed activated vessel endothelium with extensive CD8(+) and macrophage cell infiltration. Peripheral blood analyses demonstrated increases in CCR7(+/-)/CD45RO(+) cells and anti-galectin antibodies. Best overall response included 8 partial responses, 22 instances of stable disease, and a disease-control rate of 67.4%. Median survival was 25.1 months. Bevacizumab influences changes in tumor vasculature and immune responses with ipilimumab administration. The combination of bevacizumab and ipilimumab can be safely administered and reveals VEGF-A blockade influences on inflammation, lymphocyte trafficking, and immune regulation. These findings provide a basis for further investigating the dual roles of angiogenic factors in blood vessel formation and immune regulation, as well as future combinations of antiangiogenesis agents and immune checkpoint blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several clinical trials have assessed the benefits of combining anti-angiogenic therapy with ICB and have demonstrated an increase in immune cell tumor infiltration and improved outcomes in patients with immune suppressed signatures compared to ICB alone”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2014
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“gp100 peptide vaccine (1) and in combination with dacarbazine chemotherapy when compared with dacarbazine alone (2).”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“gp100 peptide vaccine (1) and in combination with dacarbazine chemotherapy when compared with dacarbazine alone (2).”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“In pre-clinical animal models and in humans, VEGF has been associated with altered antitumor immune responses including the suppression of dendritic-cell maturation (3,4), proliferation of regulatory T cells, inhibition of T-cell responses (24), and accumulation of myeloid-derived suppressor cells (MDSC) (25-27).”
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“When combined with chemotherapy or interferon, bevacizumab has proven efficacious at improving the outcomes of patients with colorectal cancer, renal cell carcinoma, non-small cell lung cancer, breast cancer, ovarian cancer, and glioblastoma multiforme (7-11,33,34).”
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“The most commonly reported adverse events (any grade) were: fatigue (35), rash/desquamation (32), headache (25), and cough (23).”
Self-citationWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · cited 1×
“Previous studies have demonstrated the effects of ipilimumab on vessels feeding tumor deposits, resulting in an immune-mediated vasculopathy (6).”
BackgroundSelf-citationKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705 · cited 2×
“The lower bounds of both confidence intervals exceed those of Korn and colleagues (15).”
Self-citationTerme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684 · cited 1×
“In pre-clinical animal models and in humans, VEGF has been associated with altered antitumor immune responses including the suppression of dendritic-cell maturation (3,4), proliferation of regulatory T cells, inhibition of T-cell responses (24), and accumulation of myeloid-derived suppressor cells (MDSC) (25-27).”
BackgroundShrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677 · cited 1×
“These results are consistent with previous observations of anti-VEGF treatment increasing lymphocyte tumor infiltrates in adoptive therapy models (21, 22).”
Cited by
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“…IFN-a2A metastatic RCC [ progression-free survival (Escudier et al., 2010) Bevacizumab ipilimumab advanced melanoma [ T cell infiltration (Hodi et al., 2014) Bevacizumab nivolumab NSCLC ClinicalTrials.gov identifier NCT01454102 Cancer Cell 26, November 10, 2014 ª2014 Elsevier Inc.…”
Metadata
- Authors
- Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., Friedlander, P., Flaherty, K. T., Murphy, G. F., Rodig, S., Velazquez, E. F., Mihm, M. C., Russell, S., DiPiro, P. J., Yap, J. T., Ramaiya, N., Van den Abbeele, A. D., Gargano, M., & McDermott, D.
- Affiliations
- Authors' Affiliations: Departments of 1Medical Oncology,
- Massachusetts General Hospital (US)
- University of Pittsburgh Medical Center (US)
- 2Biostatistics, and
- Georgetown University (US)
- Mount Sinai Hospital (US)
- 5Pathology and
- 7Tufts University;
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- 3Imaging, Dana-Farber Cancer Institute;
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Hodi, F. Stephen
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2014-07-01
- Volume
- 2
- Issue
- 7
- Pages
- 632-642
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC4306338
- OpenAlex
- W2121820529
- Cited by
- 593
- References
- 39
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 32 · 2023: 38 · 2022: 49 · 2021: 70 · 2020: 68 · 2019: 51 · 2018: 59 · 2017: 64 · 2016: 65 · 2015: 47 · 2014: 16
- FWCI
- 30.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA158467, R21CA143832, CA143832, 1R012CA158467)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- bevacizumab, ipilimumab, metastatic melanoma, CTLA-4 blockade, VEGF-A inhibition, immune checkpoint blockade, anti-angiogenic therapy, tumor vasculature, lymphocyte migration, CCR7, CD8+ T cells, macrophage infiltration, immune-related adverse events, combination immunotherapy
- MeSH terms
- Bevacizumab, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Staging, Neovascularization, Pathologic, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1158/2326-6066.cir-14-0053
- The paper
- Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., Friedlander, P., Flaherty, K. T., Murphy, G. F., Rodig, S., Velazquez, E. F., Mihm, M. C., Russell, S., DiPiro, P. J., Yap, J. T., . . . McDermott, D. (2014). Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-14-0053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.